Literature DB >> 22986704

Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.

Thanyawee Puthanakit1, Torsak Bunupuradah, Pope Kosalaraksa, Ung Vibol, Rawiwan Hansudewechakul, Sasiwimol Ubolyam, Tulathip Suwanlerk, Suparat Kanjanavanit, Chaiwat Ngampiyaskul, Jurai Wongsawat, Wicharn Luesomboon, Saphonn Vonthanak, Jintanat Ananworanich, Kiat Ruxrungtham.   

Abstract

Human leukocyte antigen (HLA)-B*5701 allele is associated with abacavir hypersensitivity. Limited data among Asians showed lower rates of HLA-B*5701 compared with Caucasians. In 296 children with HIV in Thailand and Cambodia, the prevalence of HLA-B*5701 was 4.0% (95% confidence interval: 1.6-8.0%) among Thai and 3.4% (95% confidence interval: 0.9-8.5%) among Cambodian children. HLA-B*5701 carriage is not uncommon among Thai and Cambodian children; it is close to the prevalence found in European and higher than the prevalence found in East Asian and African studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22986704      PMCID: PMC3955121          DOI: 10.1097/INF.0b013e3182745dba

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

1.  Distribution of HLA-B alleles in nasopharyngeal carcinoma patients and normal controls in Thailand.

Authors:  Nattiya Pimtanothai; P Charoenwongse; A Mutirangura; C K Hurley
Journal:  Tissue Antigens       Date:  2002-03

2.  Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.

Authors:  Cinzia Dello Russo; Lucia Lisi; Alessia Lofaro; Simona Di Giambenedetto; Bruno Federico; Giordano Madeddu; Marianna Salerno; Maria Stella Mura; Antonella Pirazzoli; Andrea de Luca; Roberto Cauda; Pierluigi Navarra
Journal:  Pharmacogenomics       Date:  2011-04       Impact factor: 2.533

3.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

Authors:  S Hetherington; S McGuirk; G Powell; A Cutrell; O Naderer; B Spreen; S Lafon; G Pearce; H Steel
Journal:  Clin Ther       Date:  2001-10       Impact factor: 3.393

4.  Clinical and immunogenetic correlates of abacavir hypersensitivity.

Authors:  Elizabeth J Phillips; Gavin A Wong; Rupert Kaul; Kamnoosh Shahabi; David A Nolan; Sandra R Knowles; Annalise M Martin; Simon A Mallal; Neil H Shear
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

5.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

6.  Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population.

Authors:  S Saito; S Ota; E Yamada; H Inoko; M Ota
Journal:  Tissue Antigens       Date:  2000-12

7.  PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

Authors:  Steve Welch; Mike Sharland; E G Hermione Lyall; Gareth Tudor-Williams; Tim Niehues; Uwe Wintergerst; Torsak Bunupuradah; Marc Hainaut; Marinella Della Negra; Maria José Mellado Pena; José Tomas Ramos Amador; Guido Castelli Gattinara; Alexandra Compagnucci; Albert Faye; Carlo Giaquinto; Diana M Gibb; Kate Gandhi; Silvia Forcat; Karen Buckberry; Lynda Harper; Christoph Königs; Deepak Patel; Diane Bastiaans
Journal:  HIV Med       Date:  2009-11       Impact factor: 3.180

8.  Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?

Authors:  Wan Beom Park; Pyoeng Gyun Choe; Kyoung-Ho Song; Shinwon Lee; Hee-Chang Jang; Jae Hyun Jeon; Sang-Won Park; Myoung Hee Park; Myoung-don Oh; Kang Won Choe
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

9.  HLA-B*5701 screening for hypersensitivity to abacavir.

Authors:  Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

10.  Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

Authors:  H Green; D M Gibb; A S Walker; D Pillay; K Butler; F Candeias; G Castelli-Gattinara; A Compagnucci; M Della Negra; A de Rossi; C Feiterna-Sperling; C Giaquinto; L Harper; J Levy; Y Saidi; U Wintergerst
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

View more
  4 in total

Review 1.  Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Authors:  Ro-Lan Dao; Shih-Chi Su; Wen-Hung Chung
Journal:  Asia Pac Allergy       Date:  2015-04-29

2.  Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation.

Authors:  Hongwei Zhang; Tong Zhang; Hongxin Zhao; Ning Han; Haiwei Zhou; Yun He; Qingxia Zhao; Hong Li; Huiqin Li; Mi Zhang; Jianjian Li; Yongtao Sun; Ke Zhao; Qing Liu; Zhiying Liu; Zhen Li; Wei Xia; Yun Lan; Haolan Hu; Weiping Cai; Hao Wu
Journal:  AIDS Res Ther       Date:  2015-08-19       Impact factor: 2.250

3.  The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.

Authors:  Asalaysa Bushyakanist; Apichaya Puangpetch; Chonlaphat Sukasem; Sasisopin Kiertiburanakul
Journal:  Pharmgenomics Pers Med       Date:  2015-11-05

4.  Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.

Authors:  Didier K Ekouevi; Serge P Eholie; Malewe Kolou; Armel Poda; Zelica Diallo; Esther Konou; Tatiana Dokpomiwa; Jacques Zoungrana; Mounerou Salou; Lionèle Mba-Tchounga; André Bigot; Abdoul-Salam Ouedraogo; Marielle Bouyout-Akoutet
Journal:  BMC Immunol       Date:  2021-07-22       Impact factor: 3.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.